Comparison Overview

MANKIND PHARMA LTD

VS

Alkem Laboratories Ltd.

MANKIND PHARMA LTD

Phase 3 New Delhi, IN
Last Update: 2025-12-02
Between 750 and 799

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,001
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Alkem Laboratories Ltd.

Lower Parel, Alkem House , Mumbai, IN, 400013
Last Update: 2025-12-01
Between 750 and 799

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 15,251
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/mankind-pharma-ltd.jpeg
MANKIND PHARMA LTD
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/alkem-laboratories-ltd.jpeg
Alkem Laboratories Ltd.
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
MANKIND PHARMA LTD
100%
Compliance Rate
0/4 Standards Verified
Alkem Laboratories Ltd.
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MANKIND PHARMA LTD in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Alkem Laboratories Ltd. in 2025.

Incident History — MANKIND PHARMA LTD (X = Date, Y = Severity)

MANKIND PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries

Incident History — Alkem Laboratories Ltd. (X = Date, Y = Severity)

Alkem Laboratories Ltd. cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/mankind-pharma-ltd.jpeg
MANKIND PHARMA LTD
Incidents

No Incident

https://images.rankiteo.com/companyimages/alkem-laboratories-ltd.jpeg
Alkem Laboratories Ltd.
Incidents

No Incident

FAQ

MANKIND PHARMA LTD company demonstrates a stronger AI Cybersecurity Score compared to Alkem Laboratories Ltd. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Alkem Laboratories Ltd. company has disclosed a higher number of cyber incidents compared to MANKIND PHARMA LTD company.

In the current year, Alkem Laboratories Ltd. company and MANKIND PHARMA LTD company have not reported any cyber incidents.

Neither Alkem Laboratories Ltd. company nor MANKIND PHARMA LTD company has reported experiencing a ransomware attack publicly.

Neither Alkem Laboratories Ltd. company nor MANKIND PHARMA LTD company has reported experiencing a data breach publicly.

Neither Alkem Laboratories Ltd. company nor MANKIND PHARMA LTD company has reported experiencing targeted cyberattacks publicly.

Neither MANKIND PHARMA LTD company nor Alkem Laboratories Ltd. company has reported experiencing or disclosing vulnerabilities publicly.

Neither MANKIND PHARMA LTD nor Alkem Laboratories Ltd. holds any compliance certifications.

Neither company holds any compliance certifications.

Neither MANKIND PHARMA LTD company nor Alkem Laboratories Ltd. company has publicly disclosed detailed information about the number of their subsidiaries.

Alkem Laboratories Ltd. company employs more people globally than MANKIND PHARMA LTD company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither MANKIND PHARMA LTD nor Alkem Laboratories Ltd. holds SOC 2 Type 1 certification.

Neither MANKIND PHARMA LTD nor Alkem Laboratories Ltd. holds SOC 2 Type 2 certification.

Neither MANKIND PHARMA LTD nor Alkem Laboratories Ltd. holds ISO 27001 certification.

Neither MANKIND PHARMA LTD nor Alkem Laboratories Ltd. holds PCI DSS certification.

Neither MANKIND PHARMA LTD nor Alkem Laboratories Ltd. holds HIPAA certification.

Neither MANKIND PHARMA LTD nor Alkem Laboratories Ltd. holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Sigstore Timestamp Authority is a service for issuing RFC 3161 timestamps. Prior to 2.0.3, Function api.ParseJSONRequest currently splits (via a call to strings.Split) an optionally-provided OID (which is untrusted data) on periods. Similarly, function api.getContentType splits the Content-Type header (which is also untrusted data) on an application string. As a result, in the face of a malicious request with either an excessively long OID in the payload containing many period characters or a malformed Content-Type header, a call to api.ParseJSONRequest or api.getContentType incurs allocations of O(n) bytes (where n stands for the length of the function's argument). This vulnerability is fixed in 2.0.3.

Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
Description

Monkeytype is a minimalistic and customizable typing test. In 25.49.0 and earlier, there is improper handling of user input which allows an attacker to execute malicious javascript on anyone viewing a malicious quote submission. quote.text and quote.source are user input, and they're inserted straight into the DOM. If they contain HTML tags, they will be rendered (after some escaping using quotes and textarea tags).

Risk Information
cvss4
Base: 7.1
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

SysReptor is a fully customizable pentest reporting platform. Prior to 2025.102, there is a Stored Cross-Site Scripting (XSS) vulnerability allows authenticated users to execute malicious JavaScript in the context of other logged-in users by uploading malicious JavaScript files in the web UI. This vulnerability is fixed in 2025.102.

Risk Information
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:N
Description

Taiko Alethia is an Ethereum-equivalent, permissionless, based rollup designed to scale Ethereum without compromising its fundamental properties. In 2.3.1 and earlier, TaikoInbox._verifyBatches (packages/protocol/contracts/layer1/based/TaikoInbox.sol:627-678) advanced the local tid to whatever transition matched the current blockHash before knowing whether that batch would actually be verified. When the loop later broke (e.g., cooldown window not yet passed or transition invalidated), the function still wrote that newer tid into batches[lastVerifiedBatchId].verifiedTransitionId after decrementing batchId. Result: the last verified batch could end up pointing at a transition index from the next batch (often zeroed), corrupting the verified chain pointer.

Risk Information
cvss4
Base: 8.0
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:U/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A flaw has been found in youlaitech youlai-mall 1.0.0/2.0.0. Affected is the function getById/updateAddress/deleteAddress of the file /mall-ums/app-api/v1/addresses/. Executing manipulation can lead to improper control of dynamically-identified variables. The attack can be executed remotely. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 6.5
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
cvss3
Base: 6.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X